Innovative green technology for bio-particle engineering. Approximately 40% of new pharmaceuticals are poorly soluble in bodily fluids. In many cases this leads to poor bioavailability, and consequent undesirable side effects as a result of high compensating dosages and generally poor patient compliance. These issues will be addressed by developing a green technology for the re-engineering of pharmaceuticals with the objective of increasing bioavilability. The research programme falls within th ....Innovative green technology for bio-particle engineering. Approximately 40% of new pharmaceuticals are poorly soluble in bodily fluids. In many cases this leads to poor bioavailability, and consequent undesirable side effects as a result of high compensating dosages and generally poor patient compliance. These issues will be addressed by developing a green technology for the re-engineering of pharmaceuticals with the objective of increasing bioavilability. The research programme falls within the Designated Research Priority of Frontier Technologies for Building and Transforming Australian Industries. Read moreRead less